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ABSTRACT
This study investigated the molecular epidemiology of a clonal outbreak of multidrug-resistant
Acinetobacter baumannii that occurred between June 2003 and June 2004 in a tertiary-care hospital in
Naples, Italy. A. baumannii was isolated from 74 patients, of whom 38 were infected and 36 were
colonised. Thirty-three patients had ventilator-associated pneumonia, three had hospital-acquired
pneumonia, and two had sepsis. Genotypic analysis of 45 available A. baumannii isolates revealed two
distinct pulsed-field gel electrophoresis (PFGE) patterns. Of these, PFGE pattern 1 was represented by
isolates from 44 patients and was identical to that of an epidemic A. baumannii clone isolated in another
hospital of Naples during 2002. All A. baumannii isolates of PFGE type 1 showed identical multiresistant
antibiotypes, characterised by resistance to all antimicrobial agents tested, including carbapenems, with
the exception of colistin. In these isolates, inhibition of OXA enzymes by 200 mM NaCl reduced the
imipenem MIC by up to four-fold. Molecular analysis of antimicrobial resistance genes showed that all
A. baumannii isolates of PFGE type 1 harboured a class 1 integron containing the aacA4, orfX and blaOXA-20
gene cassettes, an ampC gene and a blaOXA-51-like allele. Moreover, a blaOXA-58-like gene surrounded by
the regulatory elements ISAba2 and ISAba3 was identified in a 30-kb plasmid from A. baumannii isolates
of PFGE type 1, but not PFGE type 2. Thus, selection of a single A. baumannii clone producing an OXA-
58-type carbapenem-hydrolysing oxacillinase was responsible for the increase in the number of
A. baumannii infections that occurred in this hospital.
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INTRODUCTION
Acinetobacter baumannii is a non-fermenting,
Gram-negative, aerobic coccobacillus that is dis-
tributed widely in the hospital environment and
is an important opportunistic pathogen respon-
sible for a variety of nosocomial infections, inclu-
ding bacteraemia, urinary tract infection,
secondary meningitis, surgical site infection, and
nosocomial and ventilator-associated pneumonia,
especially in intensive care unit (ICU) patients [1].
A. baumannii strains responsible for nosocomial
infection are resistant to a wide range of antibi-
otics, including broad-spectrum b-lactams, carba-
penems, aminoglycosides and fluoroquinolones
[1–5]. Consequently, nosocomial infections
caused by these organisms are difficult to treat.
These therapeutic difficulties are coupled with the
fact that A. baumannii has a significant capacity
for long-term survival in the hospital environ-
ment, thus favouring transmission among
patients, either via human reservoirs or via
inanimate objects and materials [1,6]. Large and
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sustained hospital outbreaks of infection caused
by the selection of multiresistant A. baumannii
clones have been described worldwide [2,7–15].
An increase in the number of cases of A. bau-
mannii infection was observed between June 2003
and June 2004 in the V. Monaldi tertiary-care
teaching hospital, Naples, Italy. The objectives of
the present study were: (i) to study the clinical
characteristics and predisposing factors of pa-
tients from whom A. baumannii had been isolated;
(ii) to assess the genetic relatedness of A. bauman-
nii isolates in the hospital during the period of
study; and (iii) to analyse the antimicrobial
susceptibility of the A. baumannii isolates and
their mechanisms of resistance.
MATERIALS AND METHODS
Setting
The V. Monaldi Hospital is a 600-bed tertiary-care teaching
hospital, located in Naples, Italy, which provides acute
medical and surgical care within several sub-specialties and
also has an active heart transplantation programme. It contains
two ICUs: a medical–surgical ICU located in two separate
large rooms with nine and eight beds, respectively, for general
and specialist surgery patients and resuscitation emergencies
(MS-ICU); and a 12-bed ICU for cardiac surgery and heart
transplantation patients (CS-ICU). The present study analysed
74 A. baumannii isolates from 74 patients in different wards of
the hospital between June 2003 and June 2004. Forty-five
isolates from 45 patients were available for further character-
isation. Of these, 12 were isolated immediately following
hospital admission (exogenous source), while the other 33
isolates were recovered from patients who had been hospital-
ised for >48 h (endogenous source). The A. baumannii isolate
from the index case was not available for further analysis.
Clinical parameters
Infection data were collected for each episode of A. baumannii
isolation in the hospital with onset within the surveillance
period. Clinical data collected included the patient’s age,
gender, days of hospital stay, days of ICU stay, sites of
infection, other pathogens, time from admission of acquisition,
medical co-morbidities and major risk-factors (e.g., urinary
catheters, intravenous catheters, mechanical ventilation). No-
socomial infections were classified according to standard CDC
definitions [16]. The Simplified Acute Physiology Score version
II (SAPS II) was calculated at the time of admission to the ICU
and at the time of first isolation of A. baumannii [17]. A. bau-
mannii was considered to be the cause of an infection when the
SAPS II score increased at the time of A. baumannii isolation, in
combination with clinical and radiological evidence of lower
respiratory tract or systemic involvement. A. baumannii-attrib-
utable mortality was defined as death occurring during
A. baumannii infection. A. baumannii was considered to be a
colonising organism when it was isolated from clinical
specimens, but the criteria for infection were not met [16,18].
Microbiological methods
A. baumannii isolates were obtained from clinical specimens by
standard methods, followed by isolation in pure culture on
MacConkey agar plates, and were stored at )80C in nutrient
broth containing glycerol 20% v ⁄v. All the isolates were
identified as A. baumannii using the Vitek 2 system and the ID-
GNB card for identification of Gram-negative bacilli (bio-
Me´rieux, Marcy-l’Etoile, France).
Antimicrobial susceptibility testing
Susceptibility tests were performed on all 74 isolates using
the Vitek 2 system and the AST-GN09 card (bioMe´rieux).
Further antimicrobial susceptibility studies were performed
with the 45 isolates available for further characterisation.
MICs were determined by the CLSI microdilution method
[19]. Breakpoints for colistin were those recommended by the
British Society for Antimicrobial Chemotherapy (http://
www.bsac.org.uk). Breakpoints for rifampicin were those
recommended by the CLSI for staphylococci [19]. Etest MBL
strips (AB Biodisk, Solna, Sweden) were used to evaluate
metallo-b-lactamase (MBL) activity in isolates showing inter-
mediate susceptibility or resistance to imipenem and me-
ropenem [20]. Pseudomonas aeruginosa ATCC 27853 was used
as an MBL-negative reference strain, and A. baumannii AC-
54 ⁄ 97 [21] was used as an MBL-positive reference strain. The
role of oxacillinase production in carbapenem resistance was
assessed by determining carbapenem MICs by microdilution
in the presence and absence of 200 mM NaCl, as described
previously [13]. The role of AmpC b-lactamase production
was assessed by determining carbapenem MICs by micro-
dilution in the presence and absence of cloxacillin 200 mg ⁄L
[13]. Imipenem was supplied by Merck (Rahway, NJ, USA),
meropenem by Astra Zeneca (Basiglio, Milan, Italy), and
sulbactam–ampicillin by Pfizer (Rome, Italy); all other anti-
microbial agents were obtained from Sigma-Aldrich (Milan,
Italy).
Pulsed-field gel electrophoresis (PFGE) and dendrogram
analysis
Genomic DNA was prepared from A. baumannii isolates as
described previously [22], and this was followed by restric-
tion with ApaI (New England Biolabs, Beverly, MA, USA) at
25C for 4 h. PFGE was performed on a CHEF-DRII system
(Bio-Rad, Hercules, CA, USA) for 21 h at 14C, using linear
ramped pulse times of 2–20 s at 200 V. Lambda 48.5-kb
concatamers (New England BioLabs) were used as molecular
size markers. PFGE profiles were converted to TIFF files and
photographed. DNA restriction patterns were interpreted
using the criteria of Tenover et al. [23] and following cluster
analysis using GelCompar II v. 3.5 (Applied Maths, Sint-
Martens-Latem, Belgium) with the unweighted pair-group
method with arithmetic averages (UPGMA). The Dice correla-
tion coefficient was used with a tolerance of 1% to analyse
the similarities of the banding patterns. In brief, isolates
showing more than three DNA fragment differences and a
similarity of <80% following dendrogram analysis were
considered to represent different PFGE types, while isolates
with between one and three fragment differences and a
similarity of >80% were considered to represent PFGE
subtypes.
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DNA preparation and PCR analysis
DNA was purified using the Wizard Genomic DNA purifica-
tion kit and the Wizard Plus SV minipreps DNA purification
system (Promega, Madison, WI, USA), adapted for low-copy-
number plasmids according to the manufacturer’s recommen-
dations. Molecular analysis of plasmid DNA was performed
by EcoRI endonuclease digestion and agarose gel electrophor-
esis. Amplification of the intergenic spacer (IS) region between
16S and 23S rRNA was performed using primers 5¢-GTCGTAA
CAAGGTAGCCGTA and 5¢-GGGTT(C ⁄T)CCCC(A ⁄G)TT
C(A ⁄G)GAAAT as described previously [24]. PCR amplifica-
tion of class 1 integrons and mapping of resistance genes was
also performed as described previously [25]. Primers for the
detection of class 1 integrons were targeted at the 5¢-conserved
segment (5¢-CS) and the 3¢-CS region [25]. Detection of class 1
integrons by integrase gene PCR was performed according to
the method of Koeleman et al. [26]. Sequences of ampC were
amplified using primers 5¢-GTACCTCAATTTATGCGGGC
and 5¢-GCATTCAGCACAGCATAAGC [27]. PCR-based detec-
tion of carbapenemase-encoding genes (blaIMP, blaVIM, blaSIM,
blaOXA-23-like, blaOXA-24-like, blaOXA-51-like, blaOXA-58-like) in
Acinetobacter spp. was performed as described previously
[20,28,29]. PCR identification of the IS elements surrounding
blaOXA-58-like genes was also performed as described previ-
ously [30].
DNA sequencing and computer analysis of sequencing data
Direct sequencing of gel-purified PCR products was per-
formed using the ABI Prism BigDye Terminator v.3.0 ready
reaction cycle sequencing kit and the Applied Biosystems 3100
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA)
as recommended by the manufacturer. Similarity searches of
the DNA sequences obtained were performed against nucleic
acid sequence databases using an updated version of the
BLAST program [31].
Outer-membrane protein profiles
As carbapenem resistance in multidrug-resistant clinical iso-
lates of A. baumannii has been associated previously with the
loss of 25 ⁄ 29-kDa outer-membrane proteins [32], outer-mem-
brane protein fractions were prepared by sonication and
solubilisation in sodium lauroyl sarcosinate 2% w ⁄v and were
analysed by SDS-PAGE under reducing conditions as des-
cribed previously [33].
Statistical analysis
All statistical analyses were performed using SPSS v.11.0 (SPSS
Inc., Chicago, IL, USA). Univariate analysis was conducted
using Pearson’s chi-square test for categorical variables and
the Mann–Whitney U-test for continuous variables. The a
value was set at p £0.05.
RESULTS
Molecular epidemiology of A. baumannii
colonisation and infection in the hospital
Rapid emergence of multidrug-resistant A. bau-
mannii was observed in the hospital studied. In
the previous 18 months, only one sporadic A. bau-
mannii isolate was obtained from the CS-ICU of
the hospital, while no isolates were obtained from
other wards of the hospital. Between June 2003
and June 2004, A. baumannii was isolated from 74
patients: 57 in the MS-ICU, 11 in the CS-ICU and
six from other wards of the hospital (Fig. 1). The
index case was a patient transferred to the CS-ICU
from the ICU of another hospital in Naples. The
peak of the epidemic occurred in the MS-ICU
between late December 2003 and January 2004,
with an infection rate of 62–87% of patients with a
positive A. baumannii culture per week. Subse-
quently, only a few sporadic cases were detected,
with three new cases in June 2004 and no new
cases in July (Fig. 1).
Twenty patients, 15 from the MS-ICU, two from
the CS-ICU and three from other wards, yielded
A. baumannii upon hospital admission (exogenous
source), while 54 patients (42 from the MS-ICU,
nine from the CS-ICU and three from other
wards) yielded A. baumannii only following hos-
pitalisation (endogenous source). Three of the 20
patients with an exogenous source of A. bauman-
nii, including the index case, were transferred
from the ICU of a public general hospital in
Naples, while seven patients were transferred
from the ICUs of seven other institutions of the
city. The other ten patients with an exogenous
source of A. baumannii were admitted from their
private residences and had been hospitalised at
least once for recurring respiratory failure during
the 6-month period preceding the latest episode.
A. baumannii was isolated from the lower respir-
atory tract of 59 patients, the upper respiratory
tract of eight patients, the urinary tract of three
patients, the blood of two patients, and the
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Fig. 1. Incidence of Acinetobacter baumannii in the V.
Monaldi hospital, Naples, during 2003–2004. MS-ICU,
medical–surgical intensive care unit; CS-ICU, cardiac–
surgical intensive care unit.
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wound swabs of two patients. Other pathogens
were co-isolated from 44 of the 74 patients:
Staphylococcus aureus from 25 patients, P. aerugi-
nosa from 23 patients, and Candida albicans from 16
patients.
Based on the SAPS II score at the time of
admission to the ICU and at the time of
A. baumannii isolation, and on the presence
of clinical evidence of infection, A. baumannii
was considered to be responsible for 38 infec-
tions and 36 colonisations. Thirty-three patients
had ventilator-associated pneumonias, three had
hospital-acquired pneumonias, and two had
sepsis. Crude mortality was 58% (43 ⁄ 74), and
the A. baumannii-attributable mortality was 36%
(27 ⁄ 74). The clinical characteristics and pre-
disposing factors of patients from whom
A. baumannii was isolated are shown in Table 1.
Non-survivors had a higher median age than
survivors, but no significant difference was
observed between the ages of patients classified
as colonised or infected. No significant differ-
ences were observed in the distribution of
underlying diseases between survivors and
non-survivors, or between colonised and infected
patients. The length of ICU stay was significantly
higher for non-survivors than for survivors, and
for infected than for colonised patients. The
length of mechanical ventilation was also longer
for infected patients and for non-survivors,
although this was not statistically significant for
non-survivors vs. survivors. Moreover, ventila-
tor-associated pneumonia was observed signifi-
cantly more frequently in non-survivors than in
survivors, and in infected than in colonised
patients (Table 1).
To investigate whether the increase in the
frequency of isolation of A. baumannii from MS-
ICU and CS-ICU patients during the study
period was caused by the spread of epidemic
clones, all 45 available A. baumannii isolates,
isolated between October 2003 and June 2004,
were genotyped. The isolates were identified to
the species level by PCR amplification and
sequence analysis of the 16S)23S rRNA IS
region, which yielded a PCR product of 607 bp
with a DNA sequence identical to those reported
previously for A. baumannii (GenBank accession
numbers AY601823 and AY601824). Molecular
typing demonstrated a predominant ApaI PFGE
pattern among 44 multiresistant A. baumannii
isolates, with 42 isolates having an identical
PFGE pattern (designated PFGE type 1), and two
isolates having one additional band (designated
as PFGE type 1a).
Eleven isolates of PFGE type 1 were recov-
ered from patients upon hospital admission, of
whom seven were transferred from other hos-
pitals and four were admitted from home, while
the other 31 isolates were from patients hospi-
talised for >48 h. The two A. baumannii isolates
of PFGE type 1a were from a patient transferred
from another hospital and a patient who had
been hospitalised for >48 h. One additional
isolate had a PFGE profile that differed by at
least four DNA fragments and showed a simi-
larity of <80%; this isolate was from a patient
hospitalised for >48 h and was designated PFGE
type 2. The epidemic PFGE profile 1 was
identical to that of the epidemic A. baumannii
strain 2105F identified previously in the ICU of
University Federico II hospital in Naples during
2002, but showed a similarity to the epidemic
A. baumannii isolate 700F from the ICU of
University Federico II hospital during 1999 [11]
of <70%.
Table 1. Clinical characteristics and
predisposing factors of patients
from whom Acinetobacter baumannii
was isolated
Variable All Survivors Non-survivors p Colonised Infected p
Age, years (median) 71 68 73 0.027 71 72 0.131
Male gender 51 ⁄ 74 20 ⁄ 31 31 ⁄ 43 0.612 24 ⁄ 36 27 ⁄ 38 0.573
Cerebral lesion 18 ⁄ 74 6 ⁄ 31 12 ⁄ 43 0.559 8 ⁄ 36 10 ⁄ 38 0.780
Diabetes 27 ⁄ 74 14 ⁄ 31 13 ⁄ 43 0.483 12 ⁄ 36 15 ⁄ 38 0.709
Chronic obstructive
pulmonary disease
47 ⁄ 74 16 ⁄ 31 31 ⁄ 43 0.091 20 ⁄ 36 27 ⁄ 38 0.118
Days of hospital stay
(median)
25 29 23 0.275 22 29 0.161
Days of ICU stay
(median)
16.5 13 17 0.037 12 19 0.004
Days of mechanical
ventilation (median)
14 11 16 0.053 10 18 0.006
VAP 33 ⁄ 74 8 ⁄ 31 25 ⁄ 43 0.018 5 ⁄ 36 28 ⁄ 38 0.000
p values indicate significance between paired groups (i.e., survivors vs. non-survivors; colonised vs. infected
patients). p values considered significant (p <0.05) are indicated in bold.
ICU, intensive care unit; VAP, ventilator-associated pneumonia.
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Antimicrobial susceptibility patterns of
A. baumannii isolates
The majority of A. baumannii isolates (69 ⁄ 74) had a
multidrug-resistant antibiotype by Vitek 2 analy-
sis, characterised by resistance to all antimicrobial
agents tested, including ampicillin–sulbactam,
piperacillin–tazobactam, broad-spectrum cephalo-
sporins, carbapenems, fluoroquinolones and
aminoglycosides. Determination of MICs by
microdilution showed (Table 2) that A. baumannii
isolates of PFGE types 1 and 1a were resistant to
imipenem and rifampicin, and were intermedi-
ately-resistant to meropenem, but were suscept-
ible to colistin sulphate. In contrast, the sporadic
isolate of PFGE type 2 showed a more susceptible
antibiotype, characterised by susceptibility to the
majority of antimicrobial agents tested, but with
intermediate resistance to piperacillin–tazobactam
and rifampicin (data not shown).
Tests with Etest MBL strips showed that all
isolates of PFGE types 1 and 1a were non-
susceptible to imipenem (MICs 8–16 mg ⁄L), but
were negative for MBL production (imipenem-
EDTA MICs, 4–8 mg ⁄L). However, imipenem
MICs were reduced by up to four-fold in
the presence of 200 mM NaCl (MIC values
2–4 mg ⁄L), but not in the presence of cloxacillin
200 mg ⁄L. These data suggested that oxacillin-
ase activity, but not AmpC activity, contributed
to imipenem resistance.
Molecular analysis of antimicrobial resistance
genes in A. baumannii isolates
Additional epidemiological information was pro-
vided by molecular analysis of antimicrobial
resistance genes. PCR amplification and mapping
showed that all epidemic A. baumannii isolates of
PFGE types 1 and 1a, but not the isolate of PFGE
type 2, harboured a 2.2-kb class 1 integron. In
addition, DNA sequence analysis of two ampli-
cons from two different isolates showed the
presence of an aacA4 gene cassette, coding for
resistance to amikacin, tobramycin and netilmy-
cin, an orfX cassette, coding for an unknown gene
product, and a blaOXA-20 gene cassette, coding for
resistance to oxacillin. An ampC gene was ampli-
fied from all A. baumannii isolates of PFGE types 1
and 1a, with a sequence that was identical to that
of an ampC gene reported previously in A. bau-
mannii (GenBank accession number AJ009979).
PCR analysis of chromosomal DNA from all
A. baumannii isolates of PFGE types 1 and 1a with
degenerate primers specific for the MBL genes
that have been identified previously in Acinetob-
acter spp. [4] failed to amplify blaIMP-type, blaVIM-
type or blaSIM-type genes. Also, no amplification
products were obtained using primers for blaOXA-
23-type or blaOXA-24-type oxacillinases (data not
shown). A blaOXA-51-like gene was amplified from
all A. baumannii isolates of PFGE types 1 and 2,
and a blaOXA-58-like gene was amplified from
plasmid DNA extracted from all A. baumannii
isolates of PFGE types 1 and 1a, but not from
PFGE type 2. DNA sequence analysis of blaOXA-58
amplicons from two different isolates of PFGE
type 1 and 1a revealed a sequence identical to that
of the original blaOXA-58 gene (GenBank accession
number AY665723). Digestion of plasmid DNA
with EcoRI revealed an identical plasmid of 30 kb
in all A. baumannii isolates of PFGE types 1 and
1a. PCR analysis of IS elements surrounding
the blaOXA-58-like gene provided evidence for the
presence of ISAba2 and ISAba3 elements in the
30-kb plasmid.
SDS-PAGE analysis demonstrated similar out-
er-membrane protein profiles, consisting of two
major protein bands, with apparent molecular
sizes of 25 and 37 kDa, in carbapenem-resistant
A. baumannii isolates of PFGE types 1 and 1a, and
in carbapenem-susceptible A. baumannii isolates
of PFGE type 2 (data not shown).
DISCUSSION
A. baumannii outbreaks have been reported pre-
viously throughout Europe [2,8–15]. In Europe, it
has become clear during recent years that most
Table 2. Antibiotic susceptibility profile of 44 Acinetobacter
baumannii outbreak isolates belonging to pulsed-field gel
electrophoresis types 1 and 1a
Antibiotic
Breakpoint
MIC50
(mg ⁄L)
MIC90
(mg ⁄L)
Range
(mg ⁄L)S R
Sulbactam–ampicillin £8 ⁄ 4 ‡32 ⁄ 16 32 125 8–250
Piperacillin–tazobactam £16 ⁄ 4 ‡128 ⁄ 4 125 250 64 to >250
Ceftazidime £8 ‡32 125 250 64 to >250
Cefepime £8 ‡32 64 250 32–250
Imipenem £4 ‡16 16 16 8–64
Meropenem £4 ‡16 8 16 8–16
Amikacin £16 ‡32 125 >250 16 to >250
Gentamicin £4 ‡8 32 64 8–250
Ciprofloxacin £1 ‡4 64 250 32 to >250
Rifampicin £1 ‡4 4 16 1–32
Colistin £4 >4 2 4 1–4
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clinical isolates of A. baumannii belong to groups
of closely related strains, referred to as clones,
that spread geographically at the national or
international level [10,15,34]. The data presented
here show that a single clone of A. baumannii was
largely responsible for an outbreak that occurred
between June 2003 and June 2004 in two ICUs
and in other wards of the V. Monaldi tertiary-
care university hospital in Naples. As in previ-
ous studies, the respiratory tract was the most
frequent site of isolation of A. baumannii in ICU
patients [1,6,8,11]. However, many isolates of
A. baumannii from respiratory secretions and
urine specimens obtained from hospitalised
patients represent colonisation rather than infec-
tion [1], and the overall impact of Acinetobacter
on morbidity and mortality may vary depending
on the clinical status of the patients and the
hospital setting. An overall mortality rate of
18.9% has been reported in Spanish general
hospitals, with the mortality rate of patients with
infection (27%) being higher than that of patients
with A. baumannii colonisation (11%) [8]. Crude
mortality rates of 42.2% [35] and 61.6% [36] have
been reported for A. baumannii bacteraemia in
ICU patients, and a crude mortality rate of 40%
was reported for pneumonia caused by A. bau-
mannii in intubated ICU patients [37]. In the
present study, the crude mortality rate was 58%,
the A. baumannii-attributable mortality rate was
36%, and A. baumannii was considered to be
responsible for infections in about half (38 ⁄ 74) of
the patients. Possible explanations for the differ-
ences in crude mortality rates and the high
A. baumannii-attributable mortality rate in these
patients may be the severity of the patient’s
underlying condition and the microbiological
characteristics of the A. baumannii isolates. Thus,
it has been demonstrated that crude mortality
increases to 44% in ICU patients with ventilator-
associated pneumonia caused by imipenem-
resistant A. baumannii isolates, with an estimated
attributable mortality rate of 20% [37], while a
crude mortality rate of 34.2% has been calculated
for ventilator-associated pneumonia caused by
imipenem-sensitive isolates in the same ICU [37].
The present data also showed that the length of
ICU stay and the length of mechanical ventila-
tion were significantly higher for non-survivors
among A. baumannii-infected patients than for
survivors. It has been reported previously that
mechanical ventilation is one of the most import-
ant risk-factors for A. baumannii acquisition in
ICU patients [1,18].
The epidemiological data suggested that the
increase in the number of A. baumannii infections
in V. Monaldi hospital during 2003–2004 was
caused by the inter-hospital spread and circula-
tion in the community of a single epidemic clone.
Several measures were introduced in the MS-ICU
and CS-ICU to control the outbreak. Hand wash-
ing between each patient contact, use of separate
gloves and gowns when caring for each patient,
and repeated daily cleaning of inanimate objects
surrounding patients’ beds with chlorine solution,
were strictly enforced. Cohorting of multidrug-
resistant A. baumannii-infected and colonised pa-
tients and their care-givers was adopted. An
intensive educational programme was instituted
to disseminate the results of antimicrobial sus-
ceptibility testing and molecular typing of the
isolates among the hospital personnel, to reinforce
the need for adherence to hand washing and
glove use, and to emphasise the need for appro-
priate antibiotic therapy for A. baumannii-infected
patients. In general, most of the A. baumannii-
infected patients were treated with antibiotic
combinations that included colistin and ⁄ or rifam-
picin and carbapenems, with the addition of
other antimicrobial agents active against the
co-pathogens eventually isolated.
Multi-facility outbreaks of A. baumannii have
been reported previously in the USA and in
Europe [2,7–10,12,13,15]. A citywide clonal out-
break of multiresistant A. baumannii occurred in
15 hospitals in Brooklyn, New York, during 1999,
with 62 of 419 isolates collected belonging to a
single clone that was present in all 15 hospitals
[7]. In France, A. baumannii isolates with an
identical PFGE profile were obtained from 30
patients in different institutions and different
administrative departments between July 2003
and May 2004 [2,12]. Similarly, a single multire-
sistant clone of A. baumannii was identified in 24
hospitals in the UK, predominantly in the London
area, over a period of 3 years [10]. Moreover, two
distinct A. baumannii amplified fragment length
polymorphism genotypes spread among different
hospitals in The Netherlands during the period
1999–2001 [15].
Several studies have demonstrated that mul-
tiple antimicrobial resistance is an important
factor for the selection of A. baumannii epidemic
strains in the hospital setting [1–5]. In particular,
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the emergence of carbapenem resistance has
been reported during hospital outbreaks of
multidrug-resistant A. baumannii in the USA
and in Europe [7–13]. The A. baumannii isolates
with an epidemic PFGE profile in Naples were
resistant to the majority of antimicrobial agents
tested, including carbapenems and rifampicin,
but were susceptible to colistin. These results
suggested that oxacillinase activity, but not
AmpC or MBL activity, contributed to imipenem
resistance, and no alterations in outer-membrane
protein profiles were detected. In accordance
with previous findings [26,38,39], a class 1
integron carrying aacA4 and blaOXA-20 resistance
genes was amplified from the genomic DNA of
A. baumannii epidemic isolates, but not from the
genomic DNA of the more susceptible sporadic
isolate. Similar cassette arrays have already been
described in type 1 integrons from clinical
isolates in Italy [11,14,40], Spain [41] and France
[42], thus suggesting horizontal gene transfer of
these elements. An ampC gene was amplified
from the A. baumannii epidemic strains isolated
in V. Monaldi Hospital and may have contributed
to the selection of these strains. AmpC cephalo-
sporinase hyper-production in A. baumannii clin-
ical isolates has been demonstrated to confer
resistance to ceftazidime, but not to carbapenems
[43]. In agreement with this finding, the ceftaz-
idime MIC for the A. baumannii epidemic isolates
was decreased four-fold in the presence of
cloxacillin, while the imipenem MIC was not
affected (data not shown).
Several previous studies have demonstrated
that acquired resistance to carbapenems in A. bau-
mannii is mediated by class B b-lactamases (or
MBLs) and class D b-lactamases (or oxacillinases)
[4,12,21,28–30]. No blaIMP-type, blaVIM-type or
blaSIM-type MBL genes, or blaOXA-23-type or
blaOXA-24-type oxacillinase genes, were amplified
from A. baumannii epidemic isolates in the present
study, but blaOXA-51-type and blaOXA-58-type genes
were amplified. OXA-51-like enzymes have weak
carbapenemase activity in vitro, and are wide-
spread in A. baumannii strains, including carbape-
nem-susceptible isolates [29]. The blaOXA-58 gene
has been identified in carbapenem-resistant
A. baumannii clinical isolates from diverse geo-
graphical origins in Europe [12,44]. The presence
of the blaOXA-58 gene correlates well with the
reduction in imipenem MICs in the presence of
NaCl, and indicates that carbapenem resistance in
A. baumannii epidemic isolates is mediated, at
least in part, by the expression of blaOXA-58. The
data also indicated that the blaOXA-58 gene was
carried on a 30-kb plasmid in association with
ISAba2 and ISAba3, both of which have been
demonstrated to provide promoter sequences
enhancing blaOXA-58 expression [30]. Similarly, a
30-kb plasmid carrying a blaOXA-58 gene flanked
by ISAba2 and ISAba3 regulatory sequences was
isolated from A. baumannii epidemic isolates of
two distinct PFGE types recovered in Toulouse
and Lille, France [12,30], and a blaOXA-58 gene has
been identified recently in plasmids of different
sizes isolated from carbapenem-resistant A. bau-
mannii isolates in Italy [44]. Thus, all the above
data suggest that carbapenem resistance may
have been acquired through horizontal gene
transfer of blaOXA-58-containing plasmids.
In conclusion, the large and sustained A. bau-
mannii outbreak that occurred in V. Monaldi
Hospital in Naples was caused by the spread of
a single epidemic clone, which was probably
selected because of its resistance to the majority of
antimicrobial agents, including carbapenems. The
acquisition of a plasmid-encoded blaOXA-58-type
gene seems to be responsible, at least in part, for
the resistance to carbapenems. The incidence and
spread of epidemic A. baumannii isolates in the
hospital setting emphasises the need for strict
adherence to surveillance programmes in order to
prevent colonisation and infection by multidrug-
resistant bacteria and dissemination of antibiotic
resistance.
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